Steering Committee of 8 Neurovascular Physicians Developed to Advance Robotic Technology for Neurovascular Interventions and Acute Stroke Care
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that Aquilla “Quill” Turk, D.O. has joined the company as Chief Medical Officer, Neuroendovascular. Dr. Turk is a practicing physician at the Medical University of South Carolina where he serves as Director of the Stroke and Cerebrovascular Program, Director of the Neuroendovascular Program, and Professor with a joint appointment in the Departments of Radiology and Neurosurgery. Dr. Turk will serve alongside Dr. Aaron Grantham, Corindus’ Cardiovascular CMO, to spearhead the company’s clinical initiatives and expand robotic treatment into neurovascular procedures, specifically targeting acute ischemic stroke.
“I am pleased to welcome Dr. Turk to the Corindus team. His guidance and expertise will be critical as we expand our focus and technology to include treatment for neurovascular interventions,” stated Mark Toland, President and Chief Executive Officer of Corindus. “We strongly believe that our technology pipeline can add value across the spectrum of vascular interventions, with remote access and advanced robotic capabilities at the forefront of our strategy.”
In addition to Dr. Turk’s appointment, Corindus has established a Physician Steering Committee dedicated to Neuroendovascular Procedures, which will be led by Dr. Turk. Members include:
- Ricardo A. Hanel, M.D., Ph.D., Baptist Health System, Jacksonville, FL
- Tudor G. Jovin, M.D., University of Pittsburgh Medical Center, Pittsburgh, PA
- J. Mocco, M.D., The Mount Sinai Hospital, New York, NY
- Raul G. Nogueira, M.D., Grady Memorial Hospital, Atlanta, GA
- Vitor Mendes Pereira, M.D., MSc, Toronto Western Hospital-University Health Network, Toronto, ON
- Adnan Siddiqui, M.D., Toshiba Stroke & Vascular Research Center, UB, Buffalo, NY
- Satoshi Tateshima, M.D., Ronald Reagan UCLA Medical Center, Santa Monica, CA
- Raymond D. Turner, M.D., Medical University of South Carolina, Charleston, SC
“I look forward to partnering with the Corindus team and the company’s Neuroendovascular Steering Committee to bring robotic treatment to neurovascular care,” said Dr. Turk. “I believe that robotics will be critical to transforming the treatment paradigm for the neurovascular space. Speeding up treatment time through remote access capabilities and robotic precision will revolutionize how patients with illnesses such as acute stroke receive treatment.”
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company’s CorPath? System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.
Examples of such statements include statements regarding or such as:
- CMO Turk will spearhead Corindus’ clinical initiatives to expand robotic treatment into neurovascular procedure, specifically targeting acute ischemic stroke;
- Corindus’ strong belief that its technology pipeline can add value across the spectrum of vascular interventions, with remote access and advanced robotic capabilities at the forefront of its strategy; and
- the belief that robotics will be critical to transforming the treatment paradigm for the neurovascular space and that speeding up treatment time through remote access capabilities and robotic precision will revolutionize how patients with illnesses such as acute stroke receive treatment.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus’ website at http://www.corindus.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005043/en/
Corindus Vascular Robotics, Inc.
Kate Stanton, 508-653-3335 ext. 200
Lynn Pieper Lewis, 415-937-5402
Source: Corindus Vascular Robotics, Inc